Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2003-01-27

Last Posted Date: 2017-02-23

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT00002931

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 69

Registration Number: NCT00032032

Locations: 🇺🇸
McFarland Clinic, PC, Ames, Iowa, United States
🇺🇸
Community Cancer Center of Monroe, Monroe, Michigan, United States
🇺🇸
Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States

and more 48 locations

Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 300

Registration Number: NCT00039039

Locations: 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇮🇹
Ospedale Mariano Santo, Cosenza, Italy
🇮🇹
Ospedale San Martino, Genoa, Italy

and more 34 locations

Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 70

Registration Number: NCT00011999

Locations: 🇺🇸
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 231 locations

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: University of California, Davis

Registration Number: NCT00009750

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 250

Registration Number: NCT00003696

Locations: 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 450

Registration Number: NCT00003013

Locations: 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
🇨🇿
Radiotherapy Institute, Ostrava-Poruba, Czech Republic
🇸🇰
St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia

and more 25 locations

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: EBMT Solid Tumors Working Party

Registration Number: NCT00004921

Locations: 🇩🇪
Klinikum Nuernberg - Klinikum Nord, Nuernberg, Germany
🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇦🇹
Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria

and more 14 locations

Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 105

Registration Number: NCT00005087

Locations: 🇺🇸
Mount Diablo Medical Center, Concord, California, United States
🇺🇸
Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 232 locations

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: thiotepa
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2015-08-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 72

Registration Number: NCT00004092

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy